137 related articles for article (PubMed ID: 24112097)
1. Expression analysis of ovostatin 2 reveals its involvement in proliferation, invasion and angiogenesis of cutaneous malignant melanoma.
Huang YX; Qi J; Wang HS; Shao XB; Zeng XS; Li AM; Xu XL; Sun JF
J Dermatol; 2013 Nov; 40(11):901-10. PubMed ID: 24112097
[TBL] [Abstract][Full Text] [Related]
2. Ovostatin 2 knockdown significantly inhibits the growth, migration, and tumorigenicity of cutaneous malignant melanoma cells.
Huang YX; Song H; Tao Y; Shao XB; Zeng XS; Xu XL; Qi JL; Sun JF
PLoS One; 2018; 13(4):e0195610. PubMed ID: 29684087
[TBL] [Abstract][Full Text] [Related]
3. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
5. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
6. Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma.
Seleit IA; Samaka RM; Basha MA; Bakry OA
Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):204-13. PubMed ID: 23016467
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein D expression in cutaneous malignant melanoma.
Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
10. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
11. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma.
Chen H; Takahara M; Oba J; Xie L; Chiba T; Takeuchi S; Tu Y; Nakahara T; Uchi H; Moroi Y; Furue M
J Dermatol Sci; 2011 Oct; 64(1):39-44. PubMed ID: 21767935
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma.
Barnhill RL; Fandrey K; Levy MA; Mihm MC; Hyman B
Lab Invest; 1992 Sep; 67(3):331-7. PubMed ID: 1383607
[TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
16. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
Brychtova S; Bezdekova M; Brychta T; Tichy M
Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
[TBL] [Abstract][Full Text] [Related]
17. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
[TBL] [Abstract][Full Text] [Related]
18. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
19. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
